Craig B. Thompson

Craig B. Thompson, MD, is Director of the Thompson Laboratory at the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSKCC), where he served as President and Chief Executive Officer from 2010 to 2022. Born in 1953, Dr. Thompson earned his BS in Biochemistry from Dartmouth College (1974) and MD from the University of Pennsylvania (1977), with clinical training at Harvard Medical School and Fred Hutchinson Cancer Research Center. Dr. Thompson is a pioneer in cancer metabolism and immunometabolism. In the 1990s-2000s, he made foundational discoveries in T cell costimulation, being the first to demonstrate that CD28 regulates cytokine production and lymphocyte survival. He discovered that CTLA-4 functions by negatively regulating CD28 activation, contributions that supported the development of ipilimumab (Yervoy), the FDA-approved CTLA-4 antibody for melanoma. His landmark 2002 Immunity paper revealed that CD28 costimulation regulates T cell glucose metabolism through the PI3K/Akt pathway, laying the foundation for the field of cellular immunometabolism. In cancer metabolism, Dr. Thompson's highly cited 2009 Science review (9,500+ citations) reinterpreted the Warburg effect, establishing metabolic reprogramming as a hallmark of cancer. He discovered oncogenic metabolites (succinate, fumarate, 2-hydroxyglutarate) that inhibit tumor suppressor function, leading to new clinical trials for leukemia, gliomas, sarcomas, and bladder cancer. Elected to the National Academy of Sciences (2005), National Academy of Medicine (2002), and American Academy of Arts and Sciences (1999), Dr. Thompson has received the Watanabe Prize (2024, $100,000), ASCO Science of Oncology Award (2022), and ASBMB Vallee Award (2019). With over 291,000 citations and an h-index of 189, he has published seminal papers that reshaped our understanding of how metabolism regulates immune cell function and cancer biology.

Craig B. Thompson医学博士现任纪念斯隆-凯特琳癌症中心(MSKCC) Sloan Kettering研究所Thompson实验室主任,曾于2010至2022年担任该中心总裁兼首席执行官。Thompson博士1953年出生,1974年获达特茅斯学院生物化学学士学位,1977年获宾夕法尼亚大学医学博士学位,在哈佛医学院和Fred Hutchinson癌症研究中心完成临床培训。 Thompson博士是癌症代谢学和免疫代谢学的开创者。1990-2000年代,他在T细胞共刺激领域做出奠基性发现,首次证明CD28调控细胞因子产生和淋巴细胞存活,并发现CTLA-4通过负性调节CD28激活发挥抑制功能,这些贡献支持了FDA批准的CTLA-4抗体ipilimumab (Yervoy)治疗黑色素瘤的开发。他2002年在Immunity发表的里程碑论文揭示CD28共刺激通过PI3K/Akt通路调控T细胞葡萄糖代谢,为细胞免疫代谢学领域奠定了基础。 在癌症代谢学领域,Thompson博士2009年在Science发表的高被引综述(引用9,500+次)重新解释了Warburg效应,确立了代谢重编程作为癌症的标志性特征。他发现的致癌代谢物(琥珀酸、富马酸、2-羟基戊二酸)可抑制肿瘤抑制功能,促成了白血病、胶质瘤、肉瘤和膀胱癌新疗法的临床试验。 Thompson博士2005年当选美国国家科学院院士、2002年当选美国国家医学院院士、1999年当选美国艺术与科学院院士,获Watanabe奖(2024, 10万美元)、ASCO肿瘤学科学奖(2022)和ASBMB Vallee奖(2019)。他的研究获291,000+次引用、h指数189,发表的开创性论文重塑了我们对代谢如何调控免疫细胞功能和癌症生物学的理解。